D-2-Hydroxyglutarate in Glioma Biology.
Fu-Ju ChouYang LiuFengchao LangChunzhang YangPublished in: Cells (2021)
Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an "oncometabolite", D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting α-ketoglutarate (α-KG)/Fe(II)-dependent dioxgenases (α-KGDDs). Recent studies have revealed that D-2-HG affects DNA/histone methylation, hypoxia signaling, DNA repair, and redox homeostasis, which impacts the oncogenesis of IDH-mutated cancers. In this review, we will discuss the current understanding of D-2-HG in cancer biology, as well as the emerging opportunities in therapeutics in IDH-mutated glioma.
Keyphrases
- wild type
- dna repair
- papillary thyroid
- fluorescent probe
- aqueous solution
- low grade
- squamous cell
- living cells
- dna methylation
- dna damage
- genome wide
- childhood cancer
- small molecule
- high grade
- lymph node metastasis
- single molecule
- endothelial cells
- oxidative stress
- circulating tumor
- dna damage response
- young adults
- gene expression
- single cell
- copy number
- metal organic framework